2
Clinical Trials associated with CLL1 and CD38 dual-target CAR-T(Gracell Biotechnology Shanghai)A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
This is a single-arm, open-label, phase I dose-escalation clinical study to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual-target CAR T cell injection in r/r AML subjects.
/ TerminatedEarly Phase 1IIT Clinical Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T Injection in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
This study is a single-center clinical study. The main purpose is an IIT clinical trial to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual CAR-T injection in r/r AML subjects . The included population were patients with relapsed and refractory acute myeloid leukemia (r/r AML) .
100 Clinical Results associated with CLL1 and CD38 dual-target CAR-T(Gracell Biotechnology Shanghai)
100 Translational Medicine associated with CLL1 and CD38 dual-target CAR-T(Gracell Biotechnology Shanghai)
100 Patents (Medical) associated with CLL1 and CD38 dual-target CAR-T(Gracell Biotechnology Shanghai)
100 Deals associated with CLL1 and CD38 dual-target CAR-T(Gracell Biotechnology Shanghai)